Ductal carcinoma in situ (DCIS) is a premalignant condition, whose incidence is increasing in the current era of widespread screening mammography. While eminently treatable, there are innumerable controversies that surround this disease in terms of its diagnosis and treatment. We discuss these issues and review the data to date regarding this condition which affects roughly 20 per cent of all patients presenting with breast cancer.
Get full access to this article
View all access options for this article.
References
1.
ErnsterV.L., Ballard-BarbashR., BarlowW.E.Detection of ductal carcinoma in situ in women undergoing screening mammography.J Natl Cancer Inst2002; 94: 1546–54.
2.
PangJ.M., GorringeK.L., FoxS.B.Ductal carcinoma in situ -update on risk assessment and management.Histopathology2016; 68: 96–109.
3.
MassonS., BahlA.The management of ductal carcinoma in situ: current controversies and future directions.Clin Oncol (R Coll Radiol)2013; 25: 275–82.
4.
BuergerH., OtterbachF., SimonR.Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.J Pathol1999; 187: 396–402.
5.
BensonJ.R., WishartG.C.Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery.Lancet Oncol2013; 14: e348–57.
6.
BetsillW.L.Jr., RosenP.P., LiebermanP.H.Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone.JAMA1978; 239: 1863–7.
7.
ErnsterV.L., BarclayJ., KerlikowskeK.Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program.Arch Intern Med2000; 160: 953–8.
8.
EusebiV., FeudaleE., FoschiniM.P.Long-term follow-up of in situ carcinoma of the breast.Semin Diagn Pathol1994; 11: 223–35.
9.
PageD.L., DupontW.D., RogersL.W.Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy.Cancer1995; 76: 1197–200.
10.
LeonardG.D., SwainS.M.Ductal carcinoma in situ, complexities and challenges.J Natl Cancer Inst2004; 96: 906–20.
11.
DupontW.D., PageD.L.Risk factors for breast cancer in women with proliferative breast disease.N Engl J Med1985; 312: 146–51.
12.
BergW.A., GutierrezL., NessAiverM.S.Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.Radiology2004; 233: 830–49.
13.
KuhlC.K., SchradingS., BielingH.B.MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study.Lancet2007; 370: 485–92.
14.
BluemkeD.A., GatsonisC.A., ChenM.H.Magnetic resonance imaging of the breast prior to biopsy.JAMA2004; 292: 2735–42.
15.
ObdeijnI.M., LooC.E., RijnsburgerA.J.Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition.Breast Cancer Res Treat2010; 119: 399–407.
16.
PilewskieM., KennedyC., ShappellC.Effect of MRI on the management of ductal carcinoma in situ of the breast.Ann Surg Oncol2013; 20: 1522–9.
17.
MenellJ.H., MorrisE.A., DershawD.D.Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging.Breast J2005; 11: 382–90.
18.
FancelluA., TurnerR.M., DixonJ.M.Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ.Br J Surg2015; 102: 883–93.
19.
NarodS.A., IqbalJ., GiannakeasV.Breast cancer mortality after a diagnosis of ductal carcinoma in situ.JAMA Oncol2015; 1: 888–96.
20.
Van CleefA., AltintasS., HuizingM.Current view on ductal carcinoma in situ and importance of the margin thresholds: a review.Facts Views Vis ObGyn2014; 6: 210–8.
21.
WangS.Y., ChuH., ShamliyanT.Network meta-analysis of margin threshold for women with ductal carcinoma in situ.J Natl Cancer Inst2012; 104: 507–16.
22.
DunneC., BurkeJ.P., MorrowM.Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ.J Clin Oncol2009; 27: 1615–20.
23.
WapnirI.L., DignamJ.J., FisherB.Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.J Natl Cancer Inst2011; 103: 478–88.
24.
MorrowM., Van ZeeK.J., SolinL.J.Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ.Pract Radiat Oncol2016; 6: 287–95.
25.
MabryH., GiulianoA.E.Sentinel node mapping for breast cancer: progress to date and prospects for the future.Surg Oncol Clin N Am2007; 16: 55–70.
26.
Chin-LennL., MackL.A., TempleW.Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.Ann Surg Oncol2014; 21: 66–73.
27.
LymanG.H., GiulianoA.E., SomerfieldM.R.American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.J Clin Oncol2005; 23: 7703–20.
28.
YenT.W., HuntK.K., RossM.I.Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.J Am Coll Surg2005; 200: 516–26.
29.
FisherB., DignamJ., WolmarkN.Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.Lancet1999; 353: 1993–2000.
30.
HoughtonJ., GeorgeW.D., CuzickJ.Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.Lancet2003; 362: 95–102.
31.
CuzickJ., SestakI., PinderS.E.Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.Lancet Oncol2011; 12: 21–9.
32.
StaleyH., McCallumI., BruceJ.Postoperative tamoxifen for ductal carcinoma in situ.Cochrane Database Syst Rev2012; 10: CD007847.
33.
PetrelliF., BarniS.Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.Radiother Oncol2011; 100: 195–9.
34.
AllredD.C., AndersonS.J., PaikS.Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.J Clin Oncol2012; 30: 1268–73.
35.
ForbesJ.F., SestakI., HowellA.Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.Lancet2016; 387: 866–73.
36.
WarnbergF., GarmoH., EmdinS.Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial.J Clin Oncol2014; 32: 3613–8.
37.
DonkerM., LitiereS., WerutskyG.Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.J Clin Oncol2013; 31: 4054–9.
38.
CorreaC., McGaleP., TaylorC.Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.J Natl Cancer Inst Monogr2010; 2010: 162–77.
39.
McCormickB., WinterK., HudisC.RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.J Clin Oncol2015; 33: 709–15.
40.
QianG.W., NiX.J., WangZ.Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a surveillance, epidemiology, and end results population-based analysis.Onco Targets Ther2015; 8: 1407–18.
41.
SagaraY., FreedmanR.A., Vaz-LuisI.Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a Population-Based Longitudinal Cohort Study.J Clin Oncol2016; 34: 1190–6.
42.
SilversteinM.J.The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast.Am J Surg2003; 186: 337–43.
43.
SilversteinM.J., LagiosM.D., CraigP.H.A prognostic index for ductal carcinoma in situ of the breast.Cancer1996; 77: 2267–74.
44.
KerlikowskeK., MolinaroA.M., GauthierM.L.Bio-marker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.J Natl Cancer Inst2010; 102: 627–37.
45.
SolinL.J., GrayR., BaehnerF.L.A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.J Natl Cancer Inst2013; 105: 701–10.
46.
EssermanL.J., ThompsonI.M., ReidB.Addressing overdiagnosis and overtreatment in cancer: a prescription for change.Lancet Oncol2014; 15: e234–42.
47.
AllegraC.J., AberleD.R., GanschowP.NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS).NIH Consens State Sci Statements2009; 26: 1–27.
